BACKGROUND AND OBJECTIVES: The association of kidney function with long-term outpatient medication adherence in the elderly remains understudied. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A cohort of 2103 patients over the age of 65 years enrolled in a pharmacy benefits program after hospital discharge for myocardial infarction was studied. Using linear mixed effects models, the association of baseline kidney function with long-term adherence to recommended medications after myocardial infarction was examined, including angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs), β-blockers, and statins. The primary outcome measure was the percentage of days covered as calculated by pharmacy refill data for 12 serial 3-month intervals (totaling 36 months of follow-up). RESULTS: Overall long-term adherence to ACEIs/ARBs, β-blockers, and statins was poor. The mean percentage of days covered by 36 months was only 50% to 60% for all three medication classes. Patients with baseline kidney dysfunction had significantly lower long-term ACEI/ARB and β-blocker adherence compared with patients with higher baseline kidney function. Long-term statin adherence did not vary by baseline level of kidney function. CONCLUSIONS: Long-term medication adherence after myocardial infarction in the elderly is low, especially in patients with kidney dysfunction. Future strategies to improve medication adherence should pay special attention to the elderly with kidney dysfunction because they may be especially vulnerable to its adverse clinical consequences.
BACKGROUND AND OBJECTIVES: The association of kidney function with long-term outpatient medication adherence in the elderly remains understudied. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A cohort of 2103 patients over the age of 65 years enrolled in a pharmacy benefits program after hospital discharge for myocardial infarction was studied. Using linear mixed effects models, the association of baseline kidney function with long-term adherence to recommended medications after myocardial infarction was examined, including angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs), β-blockers, and statins. The primary outcome measure was the percentage of days covered as calculated by pharmacy refill data for 12 serial 3-month intervals (totaling 36 months of follow-up). RESULTS: Overall long-term adherence to ACEIs/ARBs, β-blockers, and statins was poor. The mean percentage of days covered by 36 months was only 50% to 60% for all three medication classes. Patients with baseline kidney dysfunction had significantly lower long-term ACEI/ARB and β-blocker adherence compared with patients with higher baseline kidney function. Long-term statin adherence did not vary by baseline level of kidney function. CONCLUSIONS: Long-term medication adherence after myocardial infarction in the elderly is low, especially in patients with kidney dysfunction. Future strategies to improve medication adherence should pay special attention to the elderly with kidney dysfunction because they may be especially vulnerable to its adverse clinical consequences.
Authors: Wolfgang C Winkelmayer; Sebastian Schneeweiss; Helen Mogun; Amanda R Patrick; Jerry Avorn; Daniel H Solomon Journal: Am J Kidney Dis Date: 2005-08 Impact factor: 8.860
Authors: George R Bailie; George Eisele; Lei Liu; Erik Roys; Margaret Kiser; Frederick Finkelstein; Robert Wolfe; Friedrich Port; Sally Burrows-Hudson; Rajiv Saran Journal: Nephrol Dial Transplant Date: 2005-03-15 Impact factor: 5.992
Authors: Michael G Shlipak; Linda F Fried; Mary Cushman; Teri A Manolio; Do Peterson; Catherine Stehman-Breen; Anthony Bleyer; Anne Newman; David Siscovick; Bruce Psaty Journal: JAMA Date: 2005-04-13 Impact factor: 56.272
Authors: Philip S Wang; Rhonda L Bohn; Eric Knight; Robert J Glynn; Helen Mogun; Jerry Avorn Journal: J Gen Intern Med Date: 2002-07 Impact factor: 5.128
Authors: Andrew B Morris; Jingjin Li; Kurt Kroenke; Tina E Bruner-England; Jim M Young; Michael D Murray Journal: Pharmacotherapy Date: 2006-04 Impact factor: 4.705
Authors: Yuka Kiyota; Sebastian Schneeweiss; Robert J Glynn; Carolyn C Cannuscio; Jerry Avorn; Daniel H Solomon Journal: Am Heart J Date: 2004-07 Impact factor: 4.749
Authors: Benjamin L Howell; Christopher A Powers; Eric D Weinhandl; Wendy L St Peter; Diane L Frankenfield Journal: J Am Soc Nephrol Date: 2012-03-08 Impact factor: 10.121
Authors: Tara I Chang; Yuanchao Zheng; Maria E Montez-Rath; Wolfgang C Winkelmayer Journal: Clin J Am Soc Nephrol Date: 2016-06-27 Impact factor: 8.237
Authors: Kelvin C W Leung; Neesh Pannu; Zhi Tan; William A Ghali; Merril L Knudtson; Brenda R Hemmelgarn; Marcello Tonelli; Matthew T James Journal: Clin J Am Soc Nephrol Date: 2014-10-15 Impact factor: 8.237
Authors: Tara I Chang; Liyan Gao; Todd M Brown; Monika M Safford; Suzanne E Judd; William M McClellan; Nita A Limdi; Paul Muntner; Wolfgang C Winkelmayer Journal: Clin J Am Soc Nephrol Date: 2012-02-16 Impact factor: 8.237
Authors: Carolyn T Thorpe; Holly C Lassila; Christine K O'Neil; Joshua M Thorpe; Joseph T Hanlon; Robert L Maher Journal: Am J Geriatr Pharmacother Date: 2012-02
Authors: Ilene H Zuckerman; Xianghua Yin; Gail B Rattinger; Stephen S Gottlieb; Linda Simoni-Wastila; Sarah A Pierce; Ting-Ying Huang; Rahul Shenolikar; Bruce Stuart Journal: J Am Geriatr Soc Date: 2012-09-24 Impact factor: 5.562